Bacteriophage therapy: A potential solution for the antibiotic resistance crisis

Journal of Infection in Developing Countries

Volumn 8, Issue 2, 2014, Pages 129-136

  Golkar, Zhabiz ^a   Bagasra, Omar ^a   Gene Pace, Donald ^a  

^a CLAFLIN UNIVERSITY   (United States)

Author keywords

Antibiotic resistance; Bacteriophage; Infectious disease

Indexed keywords

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIOPHAGES; BIOLOGICAL THERAPY; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; UNITED STATES;

EID: 84893950016     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.3573     Document Type: Review

References (63)

1. Centers for Disease Control. Antimicrobial resistance: a growing threat to public health. Atlanta: Division of Healthcare Quality Promotion; National Center for Infectious Diseases (2002) Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control.
2. Infectious Diseases Society of America (2004) Bad bugs, no drugs: as antibiotic discovery stagnates, a public health crisis brews. Alexandria, Infectious Diseases Society of America. Avaliable at http://www.fda.gov/ohrms/dockets/dockets/04s0233/04s-0233-c000005-03-IDSA-vol1.pdf
3. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355: 666-674.
4. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A (2000) Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 343: 1917-1924.
5. Grant GR, Lederman JA, Brandstetter RD (1997) T.G. Heaton, tuberculosis, and artificial pneumothorax: once again, back to the future? Chest 112: 7-8.
6. Nachega JB, Chaisson RE (2003) Tuberculosis drug resistance: a global threat. Clin Infect Dis 36: 24-30.
7. Levin AS, Barone AA, Penco J (1999) Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 28: 1008-1011.
8. Smolinski MS, Hamburg MA, Lederberg J (2003) Microbial threats to health: emergence, detection, and response. Washington, DC: Institute of Medicine.
9. Antibiotic/antimicrobial resistance: action plan. Atlanta: US Department of Health and Human Services Centers for Disease Control and Prevention. (2013) Available: http://www.cdc.gov/drugresistance/actionplan. Accessed on 20 December 2012
10. Harrison PF & Lederberg J, editors (1998) Antimicrobial Resistance: Issues and Opinions. Workshop Report. Washington, DC: National Academy Press.
11. Levy SB (2002) Factors impacting on the problem of antibiotic resistance. J. Antimicrob Chemother 49: 25-30.
12. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes J, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK (2007) Invasive methicillin resistant Staphylococcus aureus infections in the United States. JAMA 298: 1763-1771.
13. Folster JP, Johnson PJT, Jackson L, Dhulipali V, Dyer DW, Shafer WM (2009) MtrR modulates rpoH expression and levels of antimicrobial resistance in Neisseria gonorrhoeae. J Bacteriol 191: 287-297.
14. Mercante AD, Jackson L, Johnson PJ, Stringer VA, Dyer DW, Shafer WM (2012) MpeR regulates the mtr efflux locus in Neisseria gonorrhoeae and modulates antimicrobial resistance by an iron-responsive mechanism. Antimicrob Agents Chemother 56: 1491-1501.
15. Haddix AC, Teutsch SM, Corso PS, editors (2003) Prevention effectiveness: a guide to decision analysis and economic evaluation. New York: Oxford University Press p 345-357.
16. Klevens RM, Edwards JR, Richards CL Jr, Hortan T, Gaynes R, Pollock D, Cardo D (2007) Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 122: 160-166.
17. Eber MR, Laxminarayan R, Perencevich EN, Malani A (2010) Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia. Arch Intern Med 170: 347-353.
18. Filice GA, Nyman JA, Lexau C (2010) Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol 31: 365-367.
19. Facts about Antibiotic Resistance (2012) Infectious Diseases Society of America. Available at: http://www.idsociety.org/AR_Facts. Accessed on December 12, 2012.
20. Infectious Diseases Society of America(IDSA)- (2011). Facts about Antibiotic Resistance. Availble at http://www.idsociety.org/AR_Facts/ Accessed on April 5, 2011.
21. Pear R (2011) Health Official Takes Parting Shot at "Waste" By Key Obama Health Official. New York Times. Available: http://www.nytimes.com/2011/12/04/health/policy/parting-shot-at-waste-by-key-obama-health-official.html?_r=1&. Accessed 20 December 2012.
22. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE (2008) The Epidemic of Antibiotic-Resistant InfectionsA Call to Action for the Medical Community from the Infectious Diseases Society of America. Clinical Infectious Diseases 46: 155-164.
23. Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44: 159-177.
24. Infectious Diseases Society of America (2004) Bad bugs, no drugs: as antibiotic discovery stagnates, a public health crisis brews. Available: www.fda.gov/ohrms/dockets/.../04s-0233-c000005-03-IDSA-vol 1.pdf Accessed on,20 December 2012
25. Nakai M, Park T, Nakai SC (2002) Park Bacteriophage therapy of infectious diseases in aquaculture. Res. Mcrobiol 153: 13-18.
26. Cerveny KA, DePaola A, Duckworth DH, Gulig PA (2002) Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect. Immun 70: 6251-6262.
27. Keen EC (2012) Felix d'Herelle and Our Mcrobial Future. Future Mcrobiology 7: 1337-1339.
28. Adhya S, Merril C (2006) The road to phage therapy. Nature 443: 754-755.
29. Duckworth DH (1976) Who discovered bacteriophage? Bacteriol Rev 40: 793-802.
30. Kuchment A (2012) The Forgotten Cure: The Past and Future of Phage Therapy. Springer, New York. 170 p.
31. Ho K (2001) Bacteriophage therapy for bacterial infections: rekindling a memory. Perspect Biol Med 44: 1-16.
32. Sulakvelidze A, Alavidze Z, Morris GJ (2001) Antimicrob Agents Chemother 45: 649-659.
33. Weber-Dabrowska B, Mulczyk M, Gorski A (2000) Bacteriophage therapy of bacterial infections: an update of our institute's experience. Arch Immunol Ther Exp (Warsz) 48: 547-551.
34. Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, Kuroda M, Ikeuchi M, Tani T, Fujieda M, Wakiguchi H, Imai S (2005) Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 11: 211-219.
35. Kutateladze M, Adamia R (2010) Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol 28: 591-595.
36. Hausler T (2006) Viruses vs Superbugs. A Solution to the Antibiotic Crisis? London; New York: Macmillan. 256 p.
37. Kutter E (2008) Phage Therapy: Bacteriophages as naturally occurring antimicrobials. In: Goldman E, Green LH, editors. Practical Handbook of Microbiology. Boca Raton: CRC Press. 713-730.
38. Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B, Dabrowski M (1985) Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative staphylococcal infections. Arch Immunol Ther Exp (Warsz) 33: 261-273.
39. Salmon GG, Symonds M (1963) Staphlilo phage lysate therapy in chronic Staphylococcal infections. J Med Soc N J 60: 188-193.
40. Eaton MD, Bayne JS (1934) Bacteriophage therapy: Review of the principles and results of the use of bacteriophage in the treatment of infections (III) J Am Med Assoc 103: 1934-1939.
41. Schless RA (1932) Staphylococcus aureus meningitis: treatment with specific bacteriophage. Am J Dis Child 44: 813-822.
42. Straub ME, Applebaum M (1933) Studies on commercial bacteriophage products. J Am Med Assoc 100: 110-113.
43. Abuladze T, Li M, Marc Y (2008) Bacteriophages reduce experimental contamination of hard surface: Tomato, Spinach, Broccoli and ground beef by E.coli 0157:H7 Appl Environ Microbiol 74: 6230-6238.
44. Podschun R, Ullmann U (1998) Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 11: 589-603.
45. Fung CP, Chang FY, Lee SC, Hu BS, Kuo BI, Liu CY, Ho M, Siu LK. (2002) A global emerging disease of Klebsiella pneumonia liver abscess: is serotype K1 an important factor for complicated endophthalmitis? Gut 50: 420-424.
46. Cahill M, Chang B, Murray A (2000) Bilateral endogenous bacterial endophthalmitis associated with pyogenic hepatic abscess. Br J Ophthalmol 84: 14-36.
47. Chhibber S, Kaur S, Kumari S (2008) Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-meiated lobar pneumonia in mice. J Med Microbiol 12: 1508-1513.
48. Weber-Dabrowska B, Mulczyk M, Górski A (2001) Bacteriophage therapy for infections in cancer patients. Clin Appl Immunol Rev 1: 131-134.
49. Marinelli LJ, Fitz-Gibbon S, Hayes C, Bowman C, Inkeles M, Loncaric A, Russell DA, Jacobs-Sera D, Cokus S, Pellegrini M, Kim J, Miller JF, Hatfull GF, Modlin RL (2012) Propionibacterium acnes Bacteriophages Display Limited Genetic Diversity and Broad Killing Activity against Bacterial Skin Isolates. mBio 3: 5-12.
50. Sheng H, Knecht HJ, Kudva IT, Hovde CJ (2006) Application of bacteriophages to control intestinal Escherichia coliO157:H7 levels in ruminants. Appl Environ Microbiol 72: 5359-5366.
51. Sheng H, Knecht HJ (2006) Application of bacteriophages to control intestinal Escherichia coli O157:H7 levels in ruminants. Appl Environ Microbiol. 72: 5359-5366.
52. Kim KP, Klumpp J, Loessner MJ (2007) Enterobacter sakazakii bacteriophages can prevent bacterial growth in reconstituted infant formula. Int J Food Microbiol 115: 195-203.
53. Available at. http://aac.asm.org/content/45/3/649.full
54. Westwater C, Kasman LM, Schofield DA, Werner PA, Dolan, JW, Schmid MG, Norris JS (2003) Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 47: 1301-1307
55. Curtin J, Donlan R (2006) Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 50: 1268-1275.
56. Lu T, Collins J (2007) Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A 104: 1197-1202.
57. Wilkinson A, Holme S, Pitts K (2007) SASP: a novel antibacterial DNA binding protein and its targeted delivery for Staphylococcus aureus [abstract F1-2132]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society of Microbiology.
58. Setlow J, Randesi M, Adams J, Setlow B, Setlow P (1992) Mutation and killing of Escherichia coli expressing a cloned Bacillus subtilis gene whose product alters DNA conformation. J Bacteriol 174: 2943-2950.
59. Fairhead HM (2001) Inventor; Phico Therapeutics, assignee. Small acid-soluble proteins and uses thereof. UK patent EP1343896.
60. Fiorentin L, Vieira ND, Barioni W Jr (2005) Oral treatment with bacteriophages reduces the concentration of Salmonella enteritidis PT4 in caecal contents of broilers. Avian Pathol 34: 258-263.
61. Parviz MS, Mansel W (2010) In Sabour PM and Griffiths M, editors. Bacteriophages in the Control of Food- and Waterborne Pathogens. Editor. Amerdican Society for Microbiology -Medical Press p. 333
62. Kutateladze M, Adamia R (2010) Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends in Biotechnology. 28: 591-595.
63. Svoboda E (2009) The Next Phage. Popular Science. Available at: http://www.popsci.com/scitech/article/2009- 03/next-phage. Accessed on 31 March, 2009